New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:05 EDTJAZZJazz Pharmaceuticals agrees to acquire rights to defibrotide in Americas
Jazz Pharmaceuticals announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals under which a subsidiary of Jazz Pharmaceuticals will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year. As part of the agreement, Sigma-Tau would receive an upfront payment of $75M upon closing of the transaction. Sigma-Tau would be eligible to receive milestone payments of $25M upon the acceptance for filing by the FDA of the first NDA for defibrotide for VOD and up to an additional $150M based on the timing of potential FDA approval of defibrotide for VOD. Jazz expects to fund the transaction with cash on hand and that the transaction will close during the third quarter of 2014, subject to customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
07:10 EDTJAZZJazz Pharmaceuticals price target raised to $210 from $190 at UBS
UBS raised its price target on Jazz Pharmaceuticals to $210 from $190 on expectations for Xyrem sales growth, its lower tax rate and its strong balance sheet. UBS reiterated its Buy rating on Jazz Pharmaceuticals shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use